In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Biolase (BIOL – Research Report), with a price target of $1.50. The company's shares closed last Friday at $0.35, close to its 52-week low of $0.31. According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 5.7% and a 37.3% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Guardion Health Sciences, Applied DNA Sciences, and Sensus Healthcare. Currently, the analyst consensus on Biolase is a Moderate Buy with an average price target of $1.75, representing a 356.9% upside.
https://www.tipranks.com/news/blurbs/maxim-group-thinks-biolases-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral